Cellerant Therapeutics Inc., a biotechnology company developing novel hematopoietic stem cell-based cellular and antibody therapies for blood disorders and cancer, announced that patient dosing has commenced in its multi-center, open-label, randomized controlled Phase 2 clinical trial of CLT-008, a first-in-class, allogeneic, cellular therapy, in de novo acute myeloid leukemia patients receiving induction chemotherapy. "The initiation of this randomized study represents an important milestone for Cellerant and for AML patients receiving intensive chemotherapy," said Ram Mandalam, Ph.D., President and Chief Executive Officer of Cellerant Therapeutics.
http://ift.tt/1FvvSSp
http://ift.tt/1FvvSSp
No comments:
Post a Comment